Promising outcomes seen with neoadjuvant immunotherapy in early-stage melanoma treatment
For patients with metastatic melanoma, administering immunotherapy before surgery has shown to be remarkably effective. In fact, in 59% of patients, this approach is so successful that additional post-surgery treatment isn't necessary. These results come from the newly published NADINA study. Led by experts from the Netherlands Cancer Institute, the NADINA trial has been recognized as one of the top eleven clinical studies projected to greatly impact healthcare in 2024, as stipulated by
3470 likes
124 461 view